Taro Pharmaceuticals Industries Ltd. (TARO), Wednesday announced that two independent proxy advisor firms Institutional Shareholder Services and Glass Lewis & Co. have advised the company's shareholders to vote 'for' merger transaction with India-based Sun Pharmaceuticals Ltd.(SUNPHARMA,524715)
The company further stated that its Special Committee, Board of Directors, and Audit Committee also support proxy firms' move.
Earlier, Sun Pharma had proposed to acquire all outstanding shares of Taro for $43 per share in cash.
Currently, Taro's stock is trading at $42.35, down 0.17 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.